Oncotarget

Research Papers:

The relative efficacy and safety of targeted agents used in combination with chemotherapy in treating patients with untreated advanced gastric cancer: a network meta-analysis

Shuping Xie, Huixiang Zhang, Xueyan Wang, Quanxing Ge and Junhong Hu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:26959-26968. https://doi.org/10.18632/oncotarget.15923

Metrics: PDF 738 views  |   HTML 994 views  |   ?  


Abstract

Shuping Xie1,*, Huixiang Zhang2,*, Xueyan Wang1, Quanxing Ge1, Junhong Hu3

1Department of Gastroenterology, Huaihe Hospital of Henan University, Kaifeng, Henan, 475000, China

2Department of Radiotherapy, Huaihe Hospital of Henan University, Kaifeng, Henan, 475000, China

3Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan, 475000, China

*These authors contributed equally to this work

Correspondence to:

Junhong Hu, email: tangyinhuatyh@126.com

Keywords: gastric cancer, targeted therapy, efficacy and safety, network meta-analysis

Received: November 10, 2016     Accepted: February 15, 2017     Published: March 06, 2017

ABSTRACT

Gastric cancer is one of the leading mortal causes. Targeted therapy is a new type of cancer treatment, which precisely identifies and attacks cancer cells and significantly reduces side effects. In this network meta-analysis, we focused on the efficacy and safety of 12 targeted agents on gastric cancer among a total of 8,405 patients from 24 trials. Hazard ratio (HR) with 95% credible interval (CrI) were calculated for primary outcomes, including overall survival (OS) and progression-free survival (PFS), while odds ratio (OR) with 95% CrI were calculated for secondary outcomes. Surface under the cumulative ranking curve (SUCRA) were calculated to illustrate the rank probability of various agents for different outcomes. Compared with other analyzed treatments, ramucirumab is outstanding in survival outcomes. However, higher risk of hematological events should be noted during its application. Lapatinib is also efficacious in progression reduction, while it is always combined with severe gastrointestinal events. Trastuzumab is proposed for its high efficacy in improving survival rate and safety, which is proper for most patients. In conclusion, trastuzumab was recommended as the optimal targeted agent combined with chemotherapy for gastric cancer patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15923